In conclusion, our studies show that pharmacologic and genetic models of SIRT1 activation partially prevent the decrease in β-cell function specifically induced by circulating fat and therefore suggest SIRT1 as a therapeutic target to increase β-function in conditions where circulating fat is elevated, such as obesity and  Type 2 diabetes. This evidence concerns the gene SIRT1 and type 2 diabetes mellitus.